Ownership and insider activity for MetaVia Inc. (MTVA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
Price
| Price | $1.54 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-08 | Tursi James Patrick | A-Award | 17,186 | |
| 2026-06-08 | STRICKLAND D GORDON | A-Award | 17,186 | |
| 2026-06-08 | Salsbury Michael | A-Award | 17,186 | |
| 2026-06-08 | GROVES JASON L | A-Award | 17,186 | |
| 2026-06-08 | KOVEN ANDREW I | A-Award | 17,186 | |
| 2026-06-08 | Glickman Mark A | A-Award | 17,186 | |
| 2026-01-23 | Woodworth Marshall H | A-Award | 28,000 | |
| 2026-01-23 | Kim Hyung Heon | A-Award | 32,000 | |
| 2025-08-12 | Woodworth Marshall H | G-Gift | 14,200 | |
| 2025-06-30 | Glickman Mark A | A-Award | 28,147 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.0M | $18.5M | $2.8M | $13.9M | $10.1M | $16.4M | $33.4M | $22.4M | $16.0M | $10.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $24.7M | $19.0M | $3.8M | $14.1M | $10.7M | $16.6M | $33.5M | $22.5M | $16.1M | $10.9M |
| Property, Plant & Equipment | 0 | 0 | $12000 | $350000 | $285000 | $215000 | $2000 | $248000 | $167000 | $227000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $24.8M | $19.0M | $3.8M | $14.5M | $11.0M | $16.8M | $33.5M | $22.8M | $16.3M | $69.1M |
| Accounts Payable | $2.0M | $4.0M | $170000 | $638000 | $2.6M | $830000 | $708000 | $821000 | $3.9M | $1.1M |
| Short-term Debt | 0 | $1.4M | $9.4M | 0 | 0 | $26000 | 0 | 0 | 0 | $68000 |
| Total Current Liabilities | $4.1M | $6.4M | $219000 | $2.1M | $3.7M | $2.2M | $11.8M | $6.0M | $8.3M | $5.6M |
| Long-term Debt | 0 | $8.7M | $118000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $4.1M | $15.1M | $17.1M | $2.2M | $3.8M | $2.2M | $11.8M | $6.1M | $8.3M | $63.8M |
| Retained Earnings | -$27.1M | -$60.5M | -$15.6M | -$36.9M | -$66.5M | -$81.8M | -$95.8M | -$108.3M | -$135.9M | -$148.8M |
| Total Equity | $20.6M | $3.9M | -$13.3M | $12.3M | $7.2M | $14.6M | $21.8M | $16.7M | $7.9M | $5.3M |
| Total Debt | 0 | $10.0M | $9.6M | $116000 | $94000 | $71000 | 0 | $203000 | $136000 | $210000 |
| Net Debt | -$24.0M | -$8.4M | $6.7M | -$13.8M | -$10.0M | -$16.3M | -$33.4M | -$22.2M | -$15.9M | -$10.1M |
| Working Capital | $20.6M | $12.6M | $3.6M | $12.0M | $7.0M | $14.4M | $21.7M | $16.6M | $7.8M | $5.2M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.06 |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CASI · CLGN · CLSD · ENLV · KLTO · LSTA · NCNA
Explore sector: Healthcare · Biotechnology
More sections of MTVA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks